Brand Intelligence Graph
Company Overview
About ImmunoVec
ImmunoVec is developing a non-viral polymeric nanoparticle delivery platform for in vivo immune cell engineering — programming a patient's immune cells directly inside their body without the expensive ex vivo manufacturing process that makes CAR-T therapies cost $500,000-$1,000,000 per treatment. The company received a selective ARPA-H (Advanced Research Projects Agency for Health) award of up to $40.7 million in October 2025 for development of its platform.
Business Model & Competitive Advantage
ARPA-H funding is among the most selective and technically validated health research grants in the US government — the agency specifically funds technologies with potential to radically transform healthcare, not incremental improvements. ARPA-H's selection of ImmunoVec validates the non-viral in vivo CAR-T approach as a genuine national health priority with transformative potential.
Competitive Landscape 2025–2026
The platform's economic implications are significant: current CAR-T therapies require extracting patient T cells, genetically modifying them in specialized GMP facilities, expanding them in culture, and reinfusing them — a 3-4 week process costing $500,000+ per patient. ImmunoVec's in vivo approach could reduce this to an off-the-shelf infusion at 1-5% of current cost, potentially democratizing CAR-T-like immunotherapy for the 90%+ of patients who currently cannot access it.
Key Differentiators
Emerging Innovator
ImmunoVec is an emerging player bringing innovative solutions to the BioTech market.
Frequently Asked Questions
Estimated Visibility Trend (Beta)
Simulated 8-week rolling score
Based on estimated brand signals. Historical tracking coming soon.
Similar Brands
Emulate
Emulate, Inc. is a Boston-based biotechnology company that designs, manufactures, and commercializes Organ-Chip technology — micro-engineered devices lined with living human cells that replicate the m
ConcertAI
ConcertAI is a Boston-based company that combines artificial intelligence with real-world oncology data to accelerate cancer drug development and improve patient outcomes. Its platform integrates mult
DNAnexus
DNAnexus is the category-defining cloud platform for precision health data management, analysis, and collaboration. Founded in 2009 and headquartered in Mountain View, California, DNAnexus provides a
Saluda Medical
Saluda Medical is a commercial-stage medical device company that has pioneered closed-loop neuromodulation therapy for chronic pain management. Headquartered in Macquarie Park, Australia (with US oper
Tempus
Tempus AI is a technology company applying artificial intelligence to advance precision medicine across oncology, neurology, psychiatry, and cardiology. Founded in 2015 by Eric Lefkofsky (co-founder o
Schrödinger
Schrödinger was founded in 1990 by Richard Friesner and David Pearlman in New York City, building physics-based computational methods for molecular simulation. For over 30 years the company has develo
Compare ImmunoVec with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from ImmunoVec? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim ImmunoVec Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention ImmunoVec vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →